The lack of a strong cross‐sectional effect among structural imaging measures, even in regions with the earliest tau pathology, is not surprising in the preclinical phase, during which the variance due to developmental differences and other factors over the lifespan are more likely to modulate structure relative to the signal related to AD‐related neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.